Shares of ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) reached a new 52-week low during trading on Tuesday . The company traded as low as $0.20 and last traded at $0.22, with a volume of 24700 shares. The stock had previously closed at $0.21.

A number of analysts have recently commented on EPIX shares. Zacks Investment Research upgraded ESSA Pharma from a “hold” rating to a “buy” rating and set a $0.50 price objective for the company in a report on Monday, September 11th. Bloom Burton downgraded ESSA Pharma from a “buy” rating to a “hold” rating in a report on Tuesday, September 12th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $4.75.

The company has a current ratio of 1.26, a quick ratio of 1.26 and a debt-to-equity ratio of -1.32.

ILLEGAL ACTIVITY WARNING: “ESSA Pharma (EPIX) Sets New 1-Year Low at $0.20” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/12/21/essa-pharma-epix-sets-new-1-year-low-at-0-20.html.

About ESSA Pharma

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.

Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.